UK biotech Oxford Biomedica and Japan’s Santen have begun an option and licence agreement to research and develop gene therapy products for an inherited retinal disease.
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS